Bardoxolone methyl bm
Bardoxolone methyl (BM) is a synthetic triterpenoid compound developed by Reata Pharmaceuticals and licensed to Kyowa Kirin for clinical development and commercialization. BM is a nuclear factor erythroid 2-related factor 2 (Nrf2) activator that has been studied for its potential therapeutic effects in various disease conditions.
Lab products found in correlation
2 protocols using bardoxolone methyl bm
Intrathecal Administration of Bioactive Compounds
Nasal Epithelial Cell Transfection
The CNE1 and HNE1 cells were transfected by pcDNA3.0 plasmid (NC), pcDNA3.0-LAMB3 (LAMB3), shNC, shLAMB-1# or shLAMB-2# (Ribobio, China) following the manufacturer’s standard protocol.
For co-transfection, the CNE1 and HNE1 cells were co-transfected with shLAMB-2# or shNC and shFOXO3 following the manufacturer’s standard protocol.
To activate NRF2 signaling pathway, the cells were pretreated with 10 nM bardoxolone methyl (BM; Sigma-Aldrich, USA).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!